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Introduction
Arterial hypertension is a critical health problem affecting a large proportion of the global population. In recent years, substantial numbers of patients appear resistant to standard pharmacological antihypertensive treatments and poor adherence to medication regimens is a significant cause of treatment failure [1, 2] . The most commonly used classes of drug include diuretics, β-blockers, α-blockers, centrally active agents, calcium antagonists, angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers [3] .
In the vast majority of cases, the administration of up to three drugs is enough to achieve adequate blood pressure control, but a varying proportion of patients (15-30% [4, 5] ) present with resistant hypertension (RH), thus requiring the addition of more drugs [4, 6, 7] .
RH is defined as a resistance to treatment, when the standard therapeutic strategy, including appropriate lifestyle measures, plus the use of a diuretic and two other antihypertensive drugs at full dosage, fails to lower systolic blood pressure (SBP) and diastolic blood pressure (DBP) to values lower than 140 and 90 mmHg, respectively [6] . The clinical relevance of this phenomenon is supported by the worse prognosis of these patients and the high costs of more intensive pharmacological treatment and/or invasive surgery, which are often essential in the management of RH [8] [9] [10] . It is therefore of interest to discriminate between RH and pseudoresistant hypertension (PRH). The latter may depend on clinician-related factors, such as nonoptimal therapeutic regimens or therapeutic inertia [6, 11] . More frequently, patient-related factors underlie PRH including poor therapeutic adherence in a significant proportion of these patients [2, 12] .
There are several approaches to assess therapeutic adherence that must be reliable and exempt from potential censorship or manipulation of data by patients [13] . Currently, available methods are classified as indirect or direct [14] : indirect methods include questionnaires, patient interviews, diaries, pill counting and electronic monitoring of pill boxes, but the requirement of patient collaboration limits the efficacy of such methods. In contrast, direct methods, that are more intrusive but also more reliable, include directly observed therapy or therapeutic drug monitoring (TDM) which measures drug concentrations in biological matrices.
The use of TDM for evaluating therapeutic adherence has been limited by the low number of laboratories able to perform the analysis and the high variability of reported results. Several studies have investigated the prevalence of poor adherence in patients with RH and large variations in the proportion of patients with noncompliance have been reported (from 19 to 86% of patients [15] [16] [17] [18] [19] [20] ), depending on the setting, Country of evaluation and patient inclusion criteria.
Our group recently developed analytical methods for a simple and relatively fast quantification of 10 different antihypertensive drugs in human plasma and urine [21, 22] that could be exploited in the routine testing of therapeutic adherence.
The primary aim of the present work was to describe for the first time the prevalence of nonadherence in a representative sample of Italian patients with RH using TDM on plasma samples. Plasma measurements were chosen due to the greater sensitivity and better reliability compared with other biological matrices. For example, urine measurements are not suitable for some of the analysed drugs because telmisartan is poorly excreted in urine, ramipril is partially metabolized to ramiprilat and nifedipine displays major photodegradation.
We also aimed to determine clinical and/or demographic parameters associated with poor therapeutic adherence that may be of potential use for the identification of suspected cases of PRH and thereby ideal candidates for TDM.
Methods

Patient recruitment
Patients with RH were recruited at the Hypertension Unit of Città della Salute e della Scienza in Turin from January 2015 to December 2016. Blood samples were withdrawn during routine analyses. All patients gave informed consent according to local Ethics Committee indications (TDM-TO study, protocol CS/504 03/09/2015).
RH was defined as office SBP >140 mm Hg and/or office DBP > 90 mmHg, despite regular intake of maximally tolerated doses of at least three antihypertensive drugs including a diuretic for at least 6 weeks. In all patients secondary and spurious hypertension causes such as white coat RH [SBP <130 mmHg and DBP <80 at 24-h ambulatory blood pressure monitoring (ABPM)], drug related causes or manifest nonadherence, were excluded.
Medical history, anthropometric data and indirect assessment of adherence were collected the same day of blood sampling for TDM. Anthropometric variables such as age, sex, height, weight, heart rate (HR), body mass index, degree and duration of arterial hypertension, cardiovascular comorbidities, pharmacological therapy were collected for each patient.
Office SBP and DBP measurement were performed the same day of blood sampling for TDM, according to the indications provided by the European guidelines [6] .
All patients with RH underwent 24-h ABPM. In order to limit white-coat adherence, a potential bias of TDM, patients were informed about TDM at short notice, immediately asked for informed consent, and checked at irregular intervals.
In the vast majority of cases, blood sampling was performed at the expected maximum concentration (C max ) of antihypertensive medications at 0.5-2 h after intake, but trough concentrations (C trough , 12 h after the last drug intake) were also included in this study because the method used for drug measurements could successfully quantify all expected trough concentrations reported in the literature.
Patients were classified into three classes: fully adherent patients (AD) had detectable plasma concentrations of all prescribed drugs, partially adherent (PAD) patients showed detectable concentrations of only a part of all prescribed drugs, totally nonadherent (NAD) patients had undetectable concentrations of all the prescribed drugs.
BP and HR measurements
Office BP and HR were measured manually with the UA 101 (AND medical) hybrid sphygmomanometer using the appropriate cuff size for patient arm. At least three seated BP measurements taken at least 3 min apart were obtained and the mean of the three measurements were considered.
Twenty-four-hour ABPM was performed with Spacelabs 90 207 Ambulatory Blood Pressure monitors (Spacelabs Healthcare Inc., Snoqualmie, WA, USA). Ambulatory BP monitors were applied by a trained nurse on a routine working day, between 08.00 and 09.30. After initialization of devices with patient data, they were set up to measure every 15 min, both during day and during night time. Patients were instructed to conduct their normal activities during ABPM, to refrain from intense physical exercise and to avoid moving the arm or talking during cuff inflation. We applied European Society of Hypertension recommendations to define hypertension, based on ABPM averages (≥130/80 mmHg for the 24-hour average, ≥135/85 mmHg for daytime and ≥120/70 mmHg for night-time) [6] .
Finally, by subtracting day time ABPM HR from the office HR, the white coat heart rate increase (WCHR) was calculated [23] .
Indirect evaluation of adherence
Two indirect markers for adherence evaluation were used: the specialist opinion and a home-made questionnaire for self-reported adherence by willing patients (Table 1) . We developed a revised and simplified questionnaire after patient-feedback reporting problems of comprehension with the previously validated original questionnaire. Furthermore, considering our population of RH patients, we reserved particular attention to the polytherapy and added a question about social aids (this question does not contribute to the final score but was useful for statistical analyses). Three levels of adherence were identified by the questionnaire as follows: scores 0 to <6 (low, nonadherence); scores 6 to <9 (medium, partial adherence); scores 9 to 10 (high, full adherence). Clinicians following each patient were asked to note in medical records their hypotheses concerning the level of adherence of the patient on the basis of their personal experience before knowing TDM results.
Chemicals
Ultra-high performance liquid chromatography (UHPLC) grade acetonitrile (ACN) and methanol were purchased from VWR (Milan, Italy). UHPLC grade H 2 O was produced with a Milli-DI system coupled with a Synergy 185 system by Millipore (Milan, Italy). Blank plasma from healthy donors was kindly supplied by the Blood Bank of the Maria Vittoria Hospital (Turin, Italy). Atenolol (purity 99.6%), clonidine (purity >99%), doxazosin-mesylate (purity 98%), amlodipine-besylate (purity 100%), nifedipine (purity 99%), chlorthalidone (purity 99%), hydrochlorothiazide (purity 100%), ramipril (purity 100%), telmisartan (purity 99.5%) and 6,7-dimethyl-2,3-di (2-pyridyl) quinoxaline (purity 98.5%: the internal standard, IS), were purchased from Sigma-Aldrich Corporation (Milan, Italy); olmesartan (purity 99.3%) was purchased from Sequoia Research Chemicals (Pangbourne, Berkshire, UK). All powders were stored at 4°C in the dark, to prevent any possible degradation.
TDM analysis
All plasma samples were analysed by a previously published method [21] , fully validated following Food and Drug Administration guidelines [24] . Briefly, after addition of the IS, 200 μl of plasma was subjected to protein precipitation with pure ACN. After drying in a vacuum centrifuge, extracts were resuspended in 200 μl of H 2 O:ACN 90:10 (vol: vol) solution, acidified with 0.05% of formic acid, and directly analysed in UHPLC-MS/MS.
Statistical analysis
Statistical analysis was performed to identify associations between clinical/anthropometric/demographic parameters and adherence profile. Associations between categorical variables were tested by a chi-square test. Due to the non-normal distribution of data, differences in continuous variables between groups were tested by nonparametric Kruskal-Wallis (for more than two groups) or Mann-Whitney (for two groups) tests. The predictive value of clinical parameters for the adherence profile was tested through univariate and multivariate logistic regression analyses. Putative cut-off values for the prediction of adherence profiles were identified by receiver operating characteristic (ROC) curve analyses. P values <0.05 were considered statistically significant. All statistical analyses were performed using IBM SPSS software, version 24.0.
Nomenclature of targets and ligands
Key ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOL-OGY [25] ,
Results
Patient features and adherence profiles
Among 1250 patients referred to the Hypertension Unit of Turin, 145 fulfilled criteria for RH in the study period (Figure 1) . Of these, 36 had white coat RH, 22 had secondary causes of hypertension and 37 had their BP controlled by optimization of antihypertensive therapy. Fifty patients were considered as apparent RH and included in the study: 29 male and 21 female, with a median age of 56 years old (total range 41-79; Table 2 ). Thirty-nine patients answered the questionnaire, 67% of these were AD, 21% PAD and 13% NAD.
TDM on plasma samples revealed that only 58% of patients (n = 29; 20 men and nine women) were AD, 24% (n = 12; five men and seven women) were PAD and 18% (n = 9; four men and five women) were NAD, with undetectable concentrations of all prescribed drugs. There were no significant differences between men and women ( Table 2) .
The agreement between specialist opinion, the questionnaire and the result of plasma TDM was evaluated. A statistically significant concordance (P = 0.002) was observed between specialist opinion and TDM results, while no significant association was found between questionnaire and TDM results. Strikingly, all the TDM-defined NAD patients selfdefined as AD in the questionnaire.
Baseline patient characteristics, divided by adherence category, are shown in Table 2 . Differences in Office DBP and HR among adherence-based categories are shown in Figure 2 . Do you ever forget to take even only one medication per day?
2. Nell'ultima settimana, quanti giorni pensi di non aver assunto completamente la terapia in modo corretto?
•0-1
•5-7
During the last week, how many days did you take the therapy incorrectly?
•0-1 ➔2
•2-4 ➔1
•5-7 ➔ 0 3. Sei sempre stato del tutto sincero con il tuo medico curante? Are you always fully honest with your clinician?
Hai assunto correttamente la terapia ieri?
Did you take all your medication yesterday?
5. Trovi difficile assumere quotidianamente tutti i farmaci prescritti? Do you think it is difficult to take all the prescribed drugs every day?
6. Quando sei lontano da casa ricordi sempre di portare con te i farmaci? Do you always remember to bring all your medication when you go away from home?
7. Se un giorno dimentichi di assumere la terapia, ti senti in colpa? Do you feel guilty when you forget to take your therapy?
8. Da 1 a 5, quanto reputi importante curare la tua ipertensione?
•1 -assolutamente non è importante
•2 -poco importante
From 1 to 5, how much is important for you to treat your hypertension?
•1 -absolutely not important
•2 -not very important
•3 -quite important
•4 -very important
•5 -essential
•2 ➔1
•3 ➔2
•4 ➔3
•5 ➔4
9. Ti consulteresti con il tuo medico curante prima di interrompere eventualmente la terapia a causa di forti effetti collaterali?
Would you discuss with your clinician before stopping your therapy due to severe side effects? Compared with other patients, NAD patients were slightly younger (not significant), comprised significantly more smokers (P = 0.027) and had significantly higher office and 24 h SBP (P = 0.021 and P = 0.048 respectively), office and 24 h DBP (P = 0.010 and P = 0.006 respectively), office HR and WCHR (P = 0.007 and P = 0.001 respectively) and reported a high prevalence of social aids or a prepaid pension (P = 0.045). Among NAD patients, coronary artery disease and previous invasive treatments for hypertension were significantly more frequent (P = 0.043 and P = 0.001 respectively). Furthermore, a higher fraction (>20%) of NAD and PAD patients experienced a previous stroke, compared to ADs (P = 0.003).
Predictive parameters of nonadherence
Univariate logistic regression analysis identified the following parameters as putative predictors of NAD (Figure 3 ): smoking habit (P = 0.039), social aids (P = 0.056), coronary artery disease (P = 0.083), previous invasive treatment for hypertension (P = 0.004), office SBP, DBP and HR (P = 0.007, P = 0.004 and P = 0.008, respectively), 24-h ABPM SBP and 24-h ABPM DBP (P = 0.058 and P = 0.018, respectively) and WCHR (P = 0.012).
To identify parameters that could potentially identify real NAD patients, a multivariate logistic regression was performed, considering at most three variables combined. The resulting model included office DBP (P = 0.045) and office HR (not significant P-value). To define cut-off values, only considering office DBP, ROC curve analyses indicated that patients with DBP values >124.5 mmHg (area under the ROC curve = 0.805; P = 0.012; sensitivity 71.4%; specificity 97.1%) have higher probability to be NAD ( Figure S1 ).
Discussion
RH has become increasingly investigated to define its real prevalence. The impact of poor therapeutic adherence, which often impairs the results of clinical trials, is relevant but a multitude of discordant data are reported in the literature. RH patients are at high risk of nonadherence because of the high number of prescribed antihypertensive medications [26] . Moreover, fixed combinations of drugs are often unsuitable for patients or unavailable in some countries and the addition of further drugs, with the worsening of side effects, often results in further nonadherence [26] . Nonetheless RH patients exert a high economic impact on the Italian health system, because of the number of reimbursed visits, hospitalizations and prescribed pills. Moreover, these patients may potentially undergo invasive treatments and are at a higher cardiovascular risk, thus there is a substantial clinical utility to accurately discriminate between RH and PRH.
Herein, we show that 42% of RH patients were nonadherent, of whom 24% resulted partially adherent and 18% were totally nonadherent, largely in accordance with other studies with similar inclusion criteria [16] [17] [18] . These findings greatly reduce the prevalence of true RH and confirm that nonadherence is frequent in Italy where the health system provides medical reimbursement and widespread health educational programmes. Some studies have proposed even higher percentages of NAD but the inclusion criteria, that are particularly crucial for this kind of evaluation, were different. Florczak et al. enrolled only patients with tachycardia [20] : in our work, tachycardia was an important predictor of poor adherence. In fact, all our NAD patients were prescribed either a β-blocker or a centrally acting drug (or both of them), that commonly induce a heart rate decrease, and the nonassumption of these drugs causes a consequent HR higher than expected [27] . Similarly, Ceral et al. used a severe increase in BP values (BP > 150/95 mmHg) as an inclusion criterion, thereby introducing a bias for cases of poor adherence, as suggested by our data.
Another source of bias in estimating the real prevalence of RH comes from historical indirect methods often used to measure adherence, such as questionnaires. Such methods require patient collaboration and are not reliable for the detection of intentional poor adherence. In particular, the main factor that limits the accuracy of questionnaires is the inclination to over-report adherence [28] . Therefore, new methods have been developed to directly measure therapeutic adherence including TDM [12] . Nevertheless, in some cases, questionnaires can be adopted for their educative value and can be useful to build a constructive dialogue with patients to emphasize the importance of adherence [14] .
In this work we compared traditional methods for adherence assessment with TDM. We highlight that the clinician's opinion usually agrees with the results of TDM and we confirm the over-estimation of adherence and unreliability of questionnaires. In practice, only 34% of patients declared Figure 1 Flowchart showing patient enrolment and inclusion criteria. WCRH, white coat resistant hypertension concerns with adherence in the questionnaire, but these patients mainly comprised those with several comorbidities who may find it difficult to cope with a complex pill burden and/or the related side effects even if they are adherent. In contrast, all NAD patients (confirmed through TDM) declared full adherence in the questionnaire.
We also describe clinical/anamnestic, demographical and anthropometrical characteristics of nonadherent patients to identify a common profile. No significant gender differences were observed. By contrast, significant differences in age, DBP, SBP and HR were observed between different adherence groups. In particular, the worst adherence profiles were associated with globally higher BP and HR values. An association between poor adherence and previous invasive treatments was found, suggesting that the lack of effectiveness may be related to a pre-existing problem of poor compliance to therapy [29, 30] . Furthermore, total or partial nonadherence was associated with an increased prevalence of previous acute cerebrovascular events, confirming other studies [31] [32] [33] . As highlighted by Kronish et al. suboptimal levels of adherence are associated with a wide visit-to-visit BP variability, with significant fluctuations in reported BP values, a phenomenon that affects cardiovascular outcomes [34] . This could be explained by patients who had experienced stroke and invasive treatments underestimating the importance of treatment adherence. Finally, we demonstrated that office DBP and HR were the best predictors of total NAD, and HR may be explained by the total nonadherence to centrally acting drugs or β-blockers [35] , instead of a misplaced attitude towards therapy. 
Conclusion
The use of TDM as a direct method for evaluating adherence is currently producing promising results and is expected to become standard practice in the context of resistant hypertension. The phenomenon of PRH, which is still difficult to identify and manage without a systematic approach, is frequent and often undervalued. As a consequence, the improper use of invasive strategies of treatment in patients with PRH has caused worse pharmacoeconomical consequences. The identified predictors of nonadherence described in this work could serve as a useful tool to perform preliminary screening of ideal candidates to TDM analysis. In our subpopulation, through the TDM analysis and the early detection of NAD patients, some renal denervations could probably have been avoided. Considering this, we propose that this approach is cost-effective, in agreement with previous reports [36] .
The limits of this study are the lack of a psychological evaluation of nonadherence cases and of prospective followup. Therefore, further studies on larger cohorts are warranted Figure 2 Differences in office diastolic blood pressure (DBP) and office heart rate values among fully adherent (AD), partially adherent (PAD) and totally nonadherent (NAD) patients, according to Kruskal-Wallis test. TDM, therapeutic drug monitoring Figure 3 Predictive parameters of nonadherence obtained by univariate logistic regression analysis with odds ratios and 95% confidence intervals (CI)
